НовостиBenzingaGuggenheim Maintains Buy on Faeth Therapeutics, Lowers Price Target to $69 Guggenheim Maintains Buy on Faeth Therapeutics, Lowers Price Target to $69 Benzinga 2026.11.04 14:56 (GMT+0) Открыть на Benzinga Другие новости